{"name": "roflumilast", "category": "drug", "content": "Roflumilast, sold under the brand name Daxas among others, is a medication used for the treatment of chronic obstructive pulmonary disease, plaque psoriasis, seborrheic dermatitis, and atopic dermatitis. It acts as a selective, long-acting inhibitor of the enzyme phosphodiesterase-4 (PDE-4). It has anti-inflammatory effects. It was approved for medical use in the European Union in 2010, in the United States in 2011, and in Canada in 2017. It is available as a generic medication.   == Medical uses == Roflumilast is indicated for the treatment of severe chronic obstructive pulmonary disease (COPD), plaque psoriasis, seborrheic dermatitis, and atopic dermatitis, It is used in the prevention of exacerbations (lung attacks) in severe chronic obstructive pulmonary disease (COPD).   == Adverse effects == Common (1\u201310% incidence) adverse effects include diarrhea, weight loss, nausea, headache, insomnia, decreased appetite, abdominal pain, rhinitis, sinusitis, urinary tract infection, and depression.   == Society and culture ==   === Legal status === In June 2010, it was approved in the European Union for severe COPD associated with chronic bronchitis. In February 2011, it gained FDA approval in the United States for reducing COPD exacerbations.   == References ==   == Further reading == Hohlfeld JM, Schoenfeld K, Lavae-Mokhtari M, Schaumann F, Mueller M, Bredenbroeker D, et al. (August 2008). \"Roflumilast attenuates pulmonary inflammation upon segmental endotoxin challenge in healthy subjects: a randomized placebo-controlled trial\" (PDF). Pulmonary Pharmacology & Therapeutics. 21 (4): 616\u201323. doi:10.1016/j.pupt.2008.02.002. PMID 18374614. Archived (PDF) from the original on 28 August 2019. Retrieved 24 June 2019."}